Literature DB >> 28964527

Gene Therapy with the Sleeping Beauty Transposon System.

Partow Kebriaei1, Zsuzsanna Izsvák2, Suneel A Narayanavari2, Harjeet Singh3, Zoltán Ivics4.   

Abstract

The widespread clinical implementation of gene therapy requires the ability to stably integrate genetic information through gene transfer vectors in a safe, effective, and economical manner. The latest generation of Sleeping Beauty (SB) transposon vectors fulfills these requirements, and may overcome limitations associated with viral gene transfer vectors and transient nonviral gene delivery approaches that are prevalent in ongoing clinical trials. The SB system enables high-level stable gene transfer and sustained transgene expression in multiple primary human somatic cell types, thereby representing a highly attractive gene transfer strategy for clinical use. Here, we review the most important aspects of using SB for gene therapy, including vectorization as well as genomic integration features. We also illustrate the path to successful clinical implementation by highlighting the application of chimeric antigen receptor (CAR)-modified T cells in cancer immunotherapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cell-specific targeting; chimeric antigen receptor; gene therapy vectors; non-viral gene delivery; stable gene transfer; transposon/virus hybrid vectors

Mesh:

Substances:

Year:  2017        PMID: 28964527     DOI: 10.1016/j.tig.2017.08.008

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  29 in total

1.  Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.

Authors:  Yajun Zhang; Zhiwei Zhang; Yongmei Ding; Yuan Fang; Pei Wang; Wenqi Chu; Zhenlin Jin; Xintao Yang; Jiangtao Wang; Jinxing Lou; Qijun Qian
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-25       Impact factor: 4.553

2.  Rigidity and flexibility characteristics of DD[E/D]-transposases Mos1 and Sleeping Beauty.

Authors:  Christopher M Singer; Diana Joy; Donald J Jacobs; Irina V Nesmelova
Journal:  Proteins       Date:  2019-01-10

Review 3.  The Past, Present, and Future of Non-Viral CAR T Cells.

Authors:  Alex Moretti; Marianna Ponzo; Charles A Nicolette; Irina Y Tcherepanova; Andrea Biondi; Chiara F Magnani
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

4.  Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines.

Authors:  Amanda L Wooster; Trevor S Anderson; Devin B Lowe
Journal:  J Immunol Methods       Date:  2018-10-19       Impact factor: 2.303

5.  Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.

Authors:  Chiara F Magnani; Giuseppe Gaipa; Federico Lussana; Daniela Belotti; Giuseppe Gritti; Sara Napolitano; Giada Matera; Benedetta Cabiati; Chiara Buracchi; Gianmaria Borleri; Grazia Fazio; Silvia Zaninelli; Sarah Tettamanti; Stefania Cesana; Valentina Colombo; Michele Quaroni; Giovanni Cazzaniga; Attilio Rovelli; Ettore Biagi; Stefania Galimberti; Andrea Calabria; Fabrizio Benedicenti; Eugenio Montini; Silvia Ferrari; Martino Introna; Adriana Balduzzi; Maria Grazia Valsecchi; Giuseppe Dastoli; Alessandro Rambaldi; Andrea Biondi
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 6.  Selecting a Cell Engineering Methodology During Cell Therapy Product Development.

Authors:  Lauren M Timmins; Alexandra M Burr; Kristina Carroll; Robert Keefe; Matthew Teryek; Louis J Cantolupo; Johannes C M van der Loo; Thomas R J Heathman; Adam Gormley; David Smith; Biju Parekkadan
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 7.  Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.

Authors:  Pappanaicken R Kumaresan; Thiago Aparecido da Silva; Dimitrios P Kontoyiannis
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

Review 8.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

Review 9.  Nonviral genome engineering of natural killer cells.

Authors:  Gabrielle M Robbins; Minjing Wang; Emily J Pomeroy; Branden S Moriarity
Journal:  Stem Cell Res Ther       Date:  2021-06-16       Impact factor: 6.832

Review 10.  Novel insights into gene therapy in the cornea.

Authors:  Rajiv R Mohan; Lynn M Martin; Nishant R Sinha
Journal:  Exp Eye Res       Date:  2020-11-16       Impact factor: 3.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.